FOLH1 and posterior cortical atrophy: Positron emission tomography (PET) is an integral part of PCa management, with prostate-specific membrane antigen (PSMA)-targeted tracers used for primary staging and also in the evaluation of biochemical relapse, assisting in therapy planning and disease management [3, 4].